Literature DB >> 26965143

Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination.

Rebecca A Frum1, Ian M Love1, Priyadarshan K Damle1, Nitai D Mukhopadhyay2, Swati Palit Deb3, Sumitra Deb3, Steven R Grossman4.   

Abstract

UNLABELLED: Many mutant p53 proteins exhibit an abnormally long half-life and overall increased abundance compared with wild-type p53 in tumors, contributing to mutant p53's gain-of-function oncogenic properties. Here, a novel mechanism is revealed for the maintenance of mutant p53 abundance in cancer that is dependent on DNA damage checkpoint activation. High-level mutant p53 expression in lung cancer cells was associated with preferential p53 monoubiquitination versus polyubiquitination, suggesting a role for the ubiquitin/proteasome system in regulation of mutant p53 abundance in cancer cells. Interestingly, mutant p53 ubiquitination status was regulated by ataxia-telangectasia mutated (ATM) activation and downstream phosphorylation of mutant p53 (serine 15), both in resting and in genotoxin-treated lung cancer cells. Specifically, either inhibition of ATM with caffeine or mutation of p53 (serine 15 to alanine) restored MDM2-dependent polyubiquitination of otherwise monoubiquitinated mutant p53. Caffeine treatment rescued MDM2-dependent proteasome degradation of mutant p53 in cells exhibiting active DNA damage signaling, and ATM knockdown phenocopied the caffeine effect. Importantly, in cells analyzed individually by flow cytometry, p53 levels were highest in cells exhibiting the greatest levels of DNA damage response, and interference with DNA damage signaling preferentially decreased the relative percentage of cells in a population with the highest levels of mutant p53. These data demonstrate that active DNA damage signaling contributes to high levels of mutant p53 via modulation of ubiquitin/proteasome activity toward p53. IMPLICATION: The ability of DNA damage checkpoint signaling to mediate accumulation of mutant p53 suggests that targeting this signaling pathway may provide therapeutic gain. Mol Cancer Res; 14(5); 423-36. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26965143      PMCID: PMC5110038          DOI: 10.1158/1541-7786.MCR-15-0363

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  36 in total

1.  Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells.

Authors:  E Reihsaus; M Kohler; S Kraiss; M Oren; M Montenarh
Journal:  Oncogene       Date:  1990-01       Impact factor: 9.867

2.  Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.

Authors:  Jie Xu; Joke Reumers; José R Couceiro; Frederik De Smet; Rodrigo Gallardo; Stanislav Rudyak; Ann Cornelis; Jef Rozenski; Aleksandra Zwolinska; Jean-Christophe Marine; Diether Lambrechts; Young-Ah Suh; Frederic Rousseau; Joost Schymkowitz
Journal:  Nat Chem Biol       Date:  2011-03-27       Impact factor: 15.040

3.  Human oncoprotein MDM2 activates the Akt signaling pathway through an interaction with the repressor element-1 silencing transcription factor conferring a survival advantage to cancer cells.

Authors:  S Singh; M Ramamoorthy; C Vaughan; W A Yeudall; S Deb; S Palit Deb
Journal:  Cell Death Differ       Date:  2012-12-14       Impact factor: 15.828

Review 4.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

5.  Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.

Authors:  A N Bullock; J Henckel; A R Fersht
Journal:  Oncogene       Date:  2000-03-02       Impact factor: 9.867

Review 6.  Mutant p53: one name, many proteins.

Authors:  William A Freed-Pastor; Carol Prives
Journal:  Genes Dev       Date:  2012-06-15       Impact factor: 11.361

7.  Hot-spot mutants of p53 core domain evince characteristic local structural changes.

Authors:  K B Wong; B S DeDecker; S M Freund; M R Proctor; M Bycroft; A R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

8.  Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors.

Authors:  Qin Li; Yun Zhang; Adel K El-Naggar; Shunbin Xiong; Peirong Yang; James G Jackson; Gilda Chau; Guillermina Lozano
Journal:  Mol Cancer Res       Date:  2014-03-05       Impact factor: 5.852

9.  Flow cytometric analysis of MDM2-mediated growth arrest.

Authors:  Rebecca Frum; Swati Palit Deb
Journal:  Methods Mol Biol       Date:  2003

Review 10.  The ubiquitous role of ubiquitin in the DNA damage response.

Authors:  Abdallah Al-Hakim; Cristina Escribano-Diaz; Marie-Claude Landry; Lara O'Donnell; Stephanie Panier; Rachel K Szilard; Daniel Durocher
Journal:  DNA Repair (Amst)       Date:  2010-11-04
View more
  9 in total

1.  There and Back Again: The Middle Earth of DNA Repair.

Authors:  Karen E Knudsen
Journal:  Mol Cancer Res       Date:  2016-10       Impact factor: 5.852

2.  Degron masking outlines degronons, co-degrading functional modules in the proteome.

Authors:  Mainak Guharoy; Tamas Lazar; Mauricio Macossay-Castillo; Peter Tompa
Journal:  Commun Biol       Date:  2022-05-11

3.  Potential malignant transformation in the gastric mucosa of immunodeficient mice with persistent Mycoplasma penetrans infection.

Authors:  Shuyan Cao; Dandan Shen; Yadong Wang; Linxi Li; Liping Zhou; Yuxue Wang
Journal:  PLoS One       Date:  2017-07-10       Impact factor: 3.240

Review 4.  Mutant p53 as a guardian of the cancer cell.

Authors:  Fiamma Mantovani; Licio Collavin; Giannino Del Sal
Journal:  Cell Death Differ       Date:  2018-12-11       Impact factor: 15.828

Review 5.  Regulators of Oncogenic Mutant TP53 Gain of Function.

Authors:  Satomi Yamamoto; Tomoo Iwakuma
Journal:  Cancers (Basel)       Date:  2018-12-20       Impact factor: 6.639

6.  TP53/miR-34a-associated signaling targets SERPINE1 expression in human pancreatic cancer.

Authors:  Shaw M Akula; Peter P Ruvolo; James A McCubrey
Journal:  Aging (Albany NY)       Date:  2020-01-27       Impact factor: 5.682

7.  Gain-of-function mutant p53 in cancer progression and therapy.

Authors:  Cen Zhang; Juan Liu; Dandan Xu; Tianliang Zhang; Wenwei Hu; Zhaohui Feng
Journal:  J Mol Cell Biol       Date:  2020-09-01       Impact factor: 6.216

8.  Studies on radiation sensitization efficacy by silymarin in colon carcinoma cells.

Authors:  Mitu Lal; Damodar Gupta
Journal:  Discoveries (Craiova)       Date:  2016-04-01

9.  Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe?

Authors:  Eziafa I Oduah; Steven R Grossman
Journal:  Cancer Biol Ther       Date:  2020-02-10       Impact factor: 4.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.